Thanks to the early FDA approval for Soliris follow-up Ultomiris, Alexion CEO Ludwig Hantson nabbed a pay raise in his first full year at the top job, with a total package even bigger than that of Celgene CEO Mark Alles.
read moreSandoz teamed up with RareGen to launch a generic to United Therapeutics’ Remodulin, which pulled in about $500 million in the U.S. last year. More: As Remodulin copies roll, United Therapeutics faces big hit to its top seller Source: fierce
read moreWith Brazil’s economy in tatters and the costs of manufacturing rising, Roche will slowly pull production out of the country, a decision that will cost hundreds of workers their jobs. More: Roche sets clock ticking for Brazil plant and 640
read moreLess than two years after revealing a multimillion-dollar upgrade plan for its plant in Macclesfield, U.K., AstraZeneca is cutting back, slashing almost 100 jobs in what a local union called a “hammer blow” to U.K. manufacturing. More: AstraZeneca to cut
read more© 1994 - 2026 B.M. Pharmaceuticals